Member Info for Basser1

Sareum’s website of potential indications for SDC-1801 are:-

Psoriasis. Market valuation of 55.7 Billion Dollars by 2032

Rheumatoid Arthritis - 34.47 dollars in 2022

Lupus. - 3,517 million dollars growing 7% 2022-2030

Inflammatory bowel Disease 20.33 billion dollars in 2022

Multiple sclerosis 31.90 billion dollars by 2030

Severe respiratory disease 14 billion dollars in 2022 with annual growth 6.5%

And there could be many more indications ( over 30 in the patent applications.

All we need to do is ace the trials. Exciting.

Should have put ? At the end.

Https://www.insidermedia.com/news/north-west/genedrive-secures-new-funding-facility

Note the similarity to Sareum’s Facility. Peel Hunt involved in both.

Sad. Very well said. The level of research and discussions of the science has been a key feature on this Board and is why so many investors here held onto their shares thru good and difficult times. Seems it is about to all come together. Well done all.

The 100k trade after hours was a buy surely?

Yep but not the rises we were used to with that amount of buying. Ce la vie!

Scheck - my close on Hargreaves shows 80-85?

Around 200k volume of buys today but bid and ask never changed. Remember this for the rest of this weeks trading

Lots of blue today. In the past this type of activity was putting us in the 7p range ( equivalent to £3.50) Since then the company has progressed significantly yet the share price is under 2p. This is an amazing bargain with the multiple treatments possible in a range of autoimmune and Cancers. Definitely hold onto your shares at all cost and if you are waiting to buy this is now your moment in my opinion.

HBD . Great. They seem to be moving at a pace!

Laz - minor point but should the ask have gone to 90?

44,738. Obvious buy but classed again as unknown. Don’t expect it to raise the share price.

Maths prof - the delayed trade was placed 1 minute before the three sells for the same amount of shares. So why did they delay the buy as ‘unknown’ at an obvious buy price whist publishing the three sells straightaway. The MMS are clearly not on our side -manipulation has been going on for some months now. We need to highlight as many examples as possible if only to remind them we (and others) know what’s going on.

Https://bit.ly/47YLMXs

Physiomics has today signed a 125k contract with an unnamed British biotech to support the development of an immune oncology molecule. No mention of the name of the company. Just wondered if it could be related to SD1802. Will soon find out.

Any thoughts on what’s behind the regular chunky after hour trades. Could it be institutional involvement?

And if we ever see SRA 737 in clinic that too would be used in combo to treat many solid tumour Cancers. There are around 20 Solid Tumours and at least half of those have a TP53 mutation which Makes them very vulnerable to chk1 (SRA 737) cell lethality.

Thanks Ahfam. Interesting. If it is based on future earnings as below, Sareum could have multiple applications in Autoimmune and Cancers. And with the advantage of oral delivery it could turn out to be a very expensive takeover?

Agreed Aber. I was a Sierra Oncology shareholder and the shorts ignored the obvious and were wiped out. This led to some winging about the takeover process which never came to anything.

Agree Potnak. The potential for SD1801 and SD1802 treating a wide range of Autoimmune and Cancers conditions will surely get a number of competing offers - leaving it late surely would be far too expensive.

Merck discontinued its CHK1 inhibitor MK8766 in 2021 and it is now going to do a Cancer Combination therapy treatment working with Physiomics. Looks like the dots may be lining up?